Euroapi Valuation
Is EAPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of EAPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: EAPI (€3.85) wird unter unserer Schätzung des Fair Value (€6.53) gehandelt.
Deutlich unter dem Marktwert: EAPI wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EAPI?
Other financial metrics that can be useful for relative valuation.
| What is EAPI's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €252.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 5.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EAPI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.7x | ||
MEDCL MedinCell | 19.8x | 41.2% | €280.3m |
BOI Boiron | 1.1x | 3.3% | €593.8m |
VETO Vetoquinol | 2.2x | 4.4% | €1.2b |
ALDVI Advicenne | 11.7x | 27.5% | €32.1m |
EAPI Euroapi | 0.2x | 1.6% | €252.3m |
Price-To-Sales gegen Gleichaltrige: EAPI ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (11.7x) mit dem Durchschnitt der anderen Unternehmen (17.6x) vergleicht.
Price to Earnings Ratio vs Industry
How does EAPI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: EAPI ist aufgrund seines Price-To-Earnings Verhältnisses (19.6x) im Vergleich zum European Pharmaceuticals Branchendurchschnitt (22.5x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is EAPI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 1.8x |
PM vs. Fair Ratio: EAPI ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (11.7x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (19.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €2.66 | €4.72 +77.6% | 48.6% | €9.00 | €2.90 | n/a | 5 |
| Mar ’25 | €4.00 | €7.20 +80.0% | 30.6% | €10.50 | €4.50 | n/a | 5 |
| Feb ’25 | €5.99 | €8.36 +39.5% | 32.7% | €11.80 | €4.50 | n/a | 5 |
| Jan ’25 | €5.73 | €8.55 +49.2% | 32.9% | €11.80 | €4.50 | n/a | 6 |
| Dec ’24 | €5.30 | €9.91 +87.1% | 33.5% | €16.00 | €5.00 | n/a | 7 |
| Nov ’24 | €5.10 | €10.66 +109.1% | 36.6% | €16.00 | €5.00 | n/a | 7 |
| Oct ’24 | €11.93 | €15.10 +26.6% | 7.9% | €16.90 | €13.00 | n/a | 7 |
| Sep ’24 | €12.64 | €15.10 +19.5% | 7.9% | €16.90 | €13.00 | n/a | 7 |
| Aug ’24 | €12.42 | €14.60 +17.6% | 9.1% | €16.90 | €13.00 | n/a | 7 |
| Jul ’24 | €10.50 | €14.87 +41.7% | 8.4% | €16.90 | €13.50 | n/a | 6 |
| Jun ’24 | €9.90 | €14.87 +50.2% | 8.4% | €16.90 | €13.50 | n/a | 6 |
| May ’24 | €10.90 | €14.87 +36.5% | 8.4% | €16.90 | €13.50 | n/a | 6 |
| Apr ’24 | €10.53 | €14.86 +41.2% | 11.2% | €18.00 | €13.50 | €2.80 | 5 |
| Mar ’24 | €15.45 | €18.70 +21.0% | 7.1% | €21.00 | €17.00 | €4.00 | 5 |
| Feb ’24 | €14.98 | €18.70 +24.8% | 7.1% | €21.00 | €17.00 | €5.99 | 5 |
| Jan ’24 | €13.85 | €18.50 +33.6% | 5.4% | €20.00 | €17.00 | €5.73 | 5 |
| Dec ’23 | €17.11 | €20.00 +16.9% | 6.3% | €22.00 | €18.00 | €5.30 | 5 |
| Nov ’23 | €18.14 | €19.67 +8.4% | 7.0% | €22.00 | €18.00 | €5.10 | 6 |
| Oct ’23 | €17.04 | €19.67 +15.4% | 7.0% | €22.00 | €18.00 | €11.93 | 6 |
| Sep ’23 | €16.12 | €18.05 +12.0% | 7.6% | €20.00 | €15.50 | €12.64 | 6 |
| Aug ’23 | €15.79 | €17.88 +13.2% | 8.0% | €20.00 | €15.50 | €12.42 | 6 |
| Jul ’23 | €15.79 | €17.88 +13.2% | 8.0% | €20.00 | €15.50 | €10.50 | 6 |
| Jun ’23 | €13.71 | €17.88 +30.4% | 8.0% | €20.00 | €15.50 | €9.90 | 6 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.